-
1.发明公开REKOMBINANTES MVA MIT DER FÄHIGKEIT ZUR EXPRESSION VON HCV STRUKTUR-ANTIGENEN 有权符合表达结构HCV抗原的能力重组MVA
公开(公告)号：EP1423525A1
公开(公告)日：2004-06-02
申请号：EP02797955.8
申请日：2002-09-05
发明人： SUTTER, Gerd , ERFLE, Volker , STAIB, Caroline , WANG, Yuan, , LI, Guangdi, , ZHU, Lixin,
IPC分类号： C12N15/863 , C12N15/39 , C12N15/51 , C12N5/10 , A61K39/285 , A61K39/29
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/525 , A61K2039/5256 , A61K2039/57 , C12N15/86 , C12N2710/24143 , C12N2770/24234 , C12N2770/24243
摘要： The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.
-
公开(公告)号：EP1021545A2
公开(公告)日：2000-07-26
申请号：EP98952614.0
申请日：1998-09-21
申请人： Bavarian Nordic Research Institute A/S , GSF-Forschungszentrum für Umwelt und Gesundheit GmbH , Universiti Malaysia Sarawak , Venture Technologies Sdn Bhd
CPC分类号： C07K14/005 , A61K39/00 , C07K16/1081 , C12N2710/24143 , C12N2770/24122 , Y02A50/386
摘要： The present invention relates to monoclonal antibodies and antigen binding fragments specific for and recognising antigenic epitopes capable of eliciting antibodies which protect against infection by dengue viruses as well as the said antigenic epitopes and their use for vaccine purposes. The present invention also relates to recombinant vaccinia viruses and for example such which are derived from the Modified Vaccinia Ankara (MVA) encoding for and capable of expressing dengue virus antigen, and the use of the same recombinant viruses encoding dengue virus antigens in vaccines. In addition the invention also relates to pharmaceutical compositions comprising the above monoclonal antibodies, pharmaceutical compositions comprising dengue virus antigens, and pharmaceutical compositions comprising dengue virus antigen expression vectors.
-
公开(公告)号：EP1851320A1
公开(公告)日：2007-11-07
申请号：EP06703897.6
申请日：2006-01-24
发明人： DREXLER, Ingo , SUTTER, Gerd , GASTEIGER, Georg , ERFLE, Volker
IPC分类号： C12N15/863 , A61K39/00 , A61K39/39
CPC分类号： C12N15/86 , A61K39/00 , A61K39/39 , A61K2039/5256 , C12N2710/24143 , Y02A50/386 , Y02A50/412
摘要： The present invention is directed to a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein. The present invention is further directed to a kit of parts containing said recombinant MVA as well as to a method for enhancing T cell responses in a mammal.
-
公开(公告)号：EP1425404A2
公开(公告)日：2004-06-09
申请号：EP02772289.1
申请日：2002-09-11
发明人： ERFLE, Volker , SUTTER, Gerd , HORNEMANN, Simone
CPC分类号： C12N15/86 , A61K2039/525 , C12N7/00 , C12N2710/24143 , C12N2710/24162 , Y02A50/386 , Y02A50/412
摘要： The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.
-
5.发明公开RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS ANTIGENS, AND THE USE THEREOF IN VACCINES 失效重组MVA病毒登革病毒抗原表达，其使用疫苗
公开(公告)号：EP0951555A2
公开(公告)日：1999-10-27
申请号：EP97943887.0
申请日：1997-09-23
申请人： Bavarian Nordic Research Institute A/S , University Malaysia Sarawak , GSF-FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT, GMBH
发明人： CARDOSA, Mary Jane , SUTTER, Gerd , ERFLE, Volker
CPC分类号： C12N15/86 , A61K39/00 , C07K14/005 , C12N2710/24143 , C12N2770/24122 , C12N2770/24134 , Y02A50/386
摘要： Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.
-
公开(公告)号：EP1668142A1
公开(公告)日：2006-06-14
申请号：EP04765665.7
申请日：2004-09-28
IPC分类号： C12N15/86 , A61K39/285 , A61P37/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/285 , A61K2039/5252 , A61K2039/5256 , C12N2710/24143 , Y02A50/386 , Y02A50/412
摘要： The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases. The construction of MVA IL1 beta R deletion mutants allowed to analyze the significance of IL1 beta R synthesis upon in vitro and in vivo infection with MVA. The present data show that inactivation of the IL1 beta R gene is beneficial for the development of MVA vaccines.
-
公开(公告)号：EP1594970A1
公开(公告)日：2005-11-16
申请号：EP04712013.4
申请日：2004-02-18
发明人： STAIB, Caroline , LOEWEL, Marianne , ERFLE, Volker , SUTTER, Gerd
IPC分类号： C12N15/86
CPC分类号： A61K39/285 , A61K39/12 , A61K39/29 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2710/24122 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234 , Y02A50/386 , Y02A50/412
摘要： The present invention relates to MVA mutants, which can be used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs.
-
8.发明公开REKOMBINANTE MVA-STAMME ALS POTENTIELLE IMPFSTOFFE GEGEN P. FALCIPARUM -MALARIA 有权对恶性疟原虫-MALARIA重组MVA部族潜在的疫苗
公开(公告)号：EP1554383A1
公开(公告)日：2005-07-20
申请号：EP03769329.8
申请日：2003-09-26
发明人： SUTTER, Gerd , BUJARD, Hermann , WESTERFELD, Nicole , MIAO, Jun
IPC分类号： C12N15/30 , C12N15/863 , A61K39/002
CPC分类号： C12N15/86 , A61K39/015 , A61K2039/5256 , C12N2710/24143 , Y02A50/412
摘要： The invention relates to MVA-based recombinant viruses comprising at least one nucleic acid coding for Plasmodium falciparum MSP-1 protein, a fragment or mutein thereof. The invention also relates to a method for the production of recombinant viruses, virus-containing vaccines and to the utilization of said recombinant viruses for the prophylaxis and/or therapy of malaria.
-
公开(公告)号：EP1504107A1
公开(公告)日：2005-02-09
申请号：EP03722604.0
申请日：2003-05-13
发明人： BAIER, Robert , BOULANGER, DeniseCancer Research UK Oncology Unit , ERLFE, Volker , SUTTER, Gerd
IPC分类号： C12N15/86 , C07K14/065 , A61K35/76 , A61K39/00 , C12N5/10
CPC分类号： A61K39/0011 , A61K48/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N15/86 , C12N2710/24043 , C12N2710/24143
摘要： The invention relates to a recombinant fowlpox virus (FWPV) and a DNA vector containing gene sequences for one such recombinant fowlpox virus. The invention also relates to a pharmaceutical composition containing said recombinant fowlpox virus or a DNA vector, to the use of said recombinant fowlpox virus for treating infectious diseases or tumour diseases, and to a method for producing said recombinant fowlpox virus or DNA vector. The invention further relates to eukaryote cells or prokaryote cells containing the recombinant DNA vector or the recombinant fowlpox virus. The invention is based on the identification of the FWPV-F11L gene as a novel insertion site for foreign DNA.
-
公开(公告)号：EP0836648B1
公开(公告)日：2003-05-07
申请号：EP96925654.4
申请日：1996-07-03
发明人： SUTTER, Gerd , OHLMANN, Marion , ERFLE, Volker
CPC分类号： C12N15/86 , A61K48/0091 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N9/0059 , C12N9/1247 , C12N2710/24143 , C12N2740/16322 , Y02A50/412
摘要： Recombinant MVA viruses containing and capable of expressing foreign genes which is inserted at the site of a naturally occuring deletion within the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigenes or therapeutic agents, and for the production of recombinant viruses for vaccines, or viral vectors for gene therapy.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.021 秒)
